CIC
PVCT

Carnegie Investment Counsel’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Carnegie Investment Counsel’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-10,000
Closed -$10K – 303
2014
Q3 		$10K Buy
+10,000
New +$9.69K ﹤0.01% 293

Other funds holding PVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Carnegie Investment Counsel's PVCT Position: Q4 2014 in Review

Carnegie Investment Counsel sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2014, closing a stake of 10,000 shares — an estimated $10K sold.

Carnegie Investment Counsel first reported a position in PVCT in Q3 2014 and held it in 1 quarter. The position peaked at $10K in Q3 2014. 39 funds tracked by Wall St. Rank hold PVCT as of Q4 2014.

  • Carnegie Investment Counsel reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2014 after selling out during the quarter.
  • Carnegie Investment Counsel sold 10,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2014, an estimated $10K.
  • Carnegie Investment Counsel first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q3 2014 and held it in 1 quarter.
  • Carnegie Investment Counsel's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $10K in Q3 2014.
  • 39 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2014.

Based on Carnegie Investment Counsel's 13F filing for Q4 2014, filed 18 Feb 2015.